US4351838A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Indane derivatives, process for their preparation, their use as pharmaceuticals and pharmaceutical compositions containing said derivatives
Assignee: Fidelity Union Bank
•
Filing: 1981-02-12
•
Granted: 1982-09-28
•
Expires: 2001-02-12
Abstract
Abstract The invention provides compounds of formula ##STR1## wherein R 1 and R 2 are alkyl, R 3 is hydrogen, alkyl, alkenyl, phenylalkyl or a group --(CH 2 --CH 2 --O) n --R 4 in which n is 1 to 3 and R 4 is hydrogen or an acid residue, and the ring A is unsubstituted or substituted, with the proviso that when R 3 is methyl the ring A is substituted. The compounds are useful in the treatment and prophylaxis of allergic conditions.
Inventors
- 👤 Klaus Hasspacher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 06:24
CPC Classifications
C; C07; C07D; C07D211/00; C07D211/04; C07D211/68; C07D211/70; A; A61; A61P; A61P37/00; A61P37/08; C07D211/06; C07D211/08; C07D211/10; C07D211/14
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
110 words
A compound of formula I ##STR8## wherein R 1 and R 2 , independently, are C 1-4 alkyl, R 3 is hydrogen; C 1-4 alkyl; C 3-5 alkenyl; C 7-10 phenylalkyl optionally substituted in the phenyl ring by halogen, C 1-4 alkyl or C 1-4 alkoxy; or a group of formula (a) --(CH.sub.2 --CH.sub.2 --O).sub.n --R.sub.4 (a) wherein n is an integer of from 1 to 3 and R 4 is hydrogen or a non-toxic acid residue which is removable by hydrolysis under physiological conditions, and the ring A is mono-or-di-substituted by fluoro, chloro or C 1-4 alkoxy groups, in free base or in pharmaceutically acceptable acid addition salt form.
Claim 2
Dependent Claim
110 words
A compound of formula I ##STR8## wherein R 1 and R 2 , independently, are C 1-4 alkyl, R 3 is hydrogen; C 1-4 alkyl; C 3-5 alkenyl; C 7-10 phenylalkyl optionally substituted in the phenyl ring by halogen, C 1-4 alkyl or C 1-4 alkoxy; or a group of formula (a) --(CH.sub.2 --CH.sub.2 --O).sub.n --R.sub.4 (a) wherein n is an integer of from 1 to 3 and R 4 is hydrogen or a non-toxic acid residue which is removable by hydrolysis under physiological conditions, and the ring A is mono-or-di-substituted by fluoro, chloro or C 1-4 alkoxy groups, in free base or in pharmaceutically acceptable acid addition salt form.
Claim 3
Dependent Claim
15 words
A compound according to claim 1 wherein R 3 is hydrogen or C 1-4 alkyl.
Claim 4
Dependent Claim
11 words
A compound according to claim 2 wherein R 3 is methyl.
Claim 5
Dependent Claim
15 words
A compound according to claim 1 wherein R 3 is a group of formula (a).
Claim 6
Dependent Claim
20 words
A compound according to claim 1 wherein, when R 3 is a group of formula (a), R 4 is hydrogen.
Claim 7
Dependent Claim
13 words
A compound according to claim 1 wherein ring A is substituted by chloro.
Claim 8
Dependent Claim
15 words
A compound according to claim 1 which is 4-(6-chloro-2,2-dimethyl-indane-1-ylidene)-1-methyl-piperidine in free base or salt form.
Claim 9
Dependent Claim
15 words
A compound according to claim 1 which is 4-(4,6-dichloro-2,2-dimethyl-indane-1-ylidene)-1-methyl-piperidine in free base or salt form.
Claim 10
Dependent Claim
15 words
A compound according to claim 1 which is 2-{2-{2-[4-(2,2-dimethyl-indane-1-ylidene)-piperidine-1-yl]-ethoxy}ethoxy}ethanol in free base or salt form.
Claim 11
Dependent Claim
15 words
A compound according to claim 1 which is 2-{2-[4-(2,2-dimethyl-indane-1-ylidene)-piperidine-1-yl]-ethoxy}ethanol in free base or salt form.
Claim 12
Dependent Claim
45 words
A method for the treatment or prophylaxis of asthma in a subject in need of such treatment, which method comprises administering to said subject an anti-asthma effective amount of a compound according to claim 1 in free base or pharmaceutically acceptable acid addition salt form.
Claim 13
Dependent Claim
39 words
A pharmaceutical composition for the treatment of asthma comprising an anti-asthma effective amount of a compound according to claim 1 in free base or pharmaceutically acceptable acid addition salt form, together with a pharmaceutically acceptable diluent or carrier therefor.
References Cited (Backward Citations)
US2916490A
Cited
US4172093A
Cited
US3328411A
Cited
PL57713B1
Cited
US3822310A
Cited
US4251655A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-27 | 1986-03-29 | 1986-09-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-27 | 1990-03-29 | 1990-09-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-27 | 1994-03-29 | 1994-09-28 | $7700.00 | Window Closed / Lapsed |